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ABSTRACT
Gain-of-function mutations of KIT are common genetic events in gas-
trointestinal stromal tumors (GISTs). To investigate the molecular char-
acteristics of KIT mutations in GISTs, 20 GISTs (14 GISTs with KIT
mutation and 6 GISTs without KIT mutation) were analyzed by two-
dimensional electrophoresis and matrix-associated laser desorption ioni-
zation mass spectrophotometry-time of flight. Comparative analysis of the
respective spot patterns on two-dimensional electrophoresis showed that
HMGB1, an intranuclear protein that interacts with several transcription
factors and plays a role in tumor metastasis after its secretion, was
overexpressed in GISTs with KIT mutation. All of the 14 GISTs with KIT
mutation, and only 2 of 6 GISTs without KIT mutation, revealed HMGB1
expression. Of the GISTs with KIT mutation, 12 (86%) showed strong
expression of HMGB1, more than three times higher in intensity than the
maximum observed in the 6 GISTs without KIT mutation by two-dimen-
sional electrophoresis analysis. The overexpression of HMGB1 was fur-
ther supported by Western blot analysis, and directly related to matrix
metalloproteinase 2 overexpression. Our results indicate that the overex-
pression of HMGB1 is common in GISTs and is related to the KIT
mutation, and that this may play a role in the tumorigenesis of GISTs
because overexpressed HMGB1 could accelerate genes related to tumor
growth and invasion.
INTRODUCTION
GISTs4 are the most common mesenchymal tumors composed of
uncommitted mesenchymal cells (1). Recent studies have described
the morphological and immunohistochemical similarities between the
ICCs and GISTs (2, 3). Immunohistochemically, tumor cells of GISTs
characteristically express CD34 and KIT, ICCs are located in and near
the circular muscle layer of the stomach and intestine, thus suggesting
that GISTs originate from stem cells that differentiate toward ICCs.
Among the molecular genetic changes reported to be related to
GISTs, gain-of-function mutations of the KIT proto-oncogene are the
most frequent and important (3–5). KIT encodes a type III receptor
kinase (6), the ligand of which is stem cell factor (7). Mutations in KIT
result in ligand-independent kinase activity and autophosphorylation
of KIT (8, 9). The KIT mutation is known to be present in 30–92% of
GISTs (5, 10–12). Mutations are reported to be most frequent in exon
11 and rare in exons 9 and 13. Deletions, insertions, and point
mutations have been reported, and mutations of exon 11 and exon 13
were reported to be gain-of-function mutations (3, 5, 11). Recent
studies have also demonstrated that STI571, an inhibitor of tyrosine
kinase, was effective at treating GISTs (13).
Although there is much experimental and clinical evidence that
gain-of-function mutations of KIT evoke uncontrolled cell prolifera-
tion and stimulate downstream signaling pathways, the specific down-
stream pathways related to tumor development and/or progression of
GISTs and the target molecules have not been elucidated. We, there-
fore, carried out a proteomic study on 20 GISTs and compared the
results with respect to the KIT mutation status.
MATERIALS AND METHODS
Tissue Samples. Twenty GISTs of the stomach were included in this study.
All of the cases were identified prospectively and consecutively in the Depart-
ment of Pathology at Yonsei University Medical Center between September
1995 and November 2000 for molecular marker studies. Among these 20
cases, 14 had previously been analyzed for chromosomal changes (14). Infor-
mation from hospital charts and clinicians was obtained on demographic
features and tumor sites. The patients included 9 females and 11 males ranging
in age from 35 to 79 years (Table 1). Thirteen colorectal carcinomas were also
selected for comparison.
For DNA and protein extraction, fresh tumors and adjacent nontumorous
smooth muscle or mucosal tissues were obtained immediately after surgical
excision and were stored at 70° before use. To enrich the tumor cell
population, areas with more than 90% of tumor cells were selected from
H&E-stained slides using the cryostat microdissection technique. Genomic
DNA was prepared using the SDS-proteinase K and phenol-chloroform ex-
traction method.
Conventional pathological parameters (tumor size, number, differentiation)
were examined prospectively without prior knowledge of the molecular data.
The GISTs were divided into three groups according to the criteria of Lewin
et al. (1). The guidelines for the diagnosis of gastric stromal tumor malignancy
are composed of two unequivocal factors (histologically confirmed metastasis
and invasion of adjacent organs) and seven high-risk factors (larger than 5.5
cm in diameter; more than five mitoses per 50 high power fields; presence of
tumor necrosis; nuclear pleomorphism; dense cellularity; microscopic invasion
into the lamina propria or blood vessels; and the presence of alveolar or cell
balls). Tumors having more than one unequivocal or two high-risk features
were categorized as malignant GISTs, tumors having only one high-risk
feature were categorized as borderline GISTs, and tumors having neither
unequivocal nor high-risk features were categorized as benign GISTs. Accord-
ing to these criteria, 4 cases were categorized as benign, 10 cases as borderline,
and 6 cases as malignant GIST (Table 1).
KIT Mutation Analysis. Somatic mutations in exons 9, 11, 13, and 17 of
KIT were detected using PCR-based assay with previously described primers
(5, 10, 11). PCR was carried out in a mixture of 20 l containing 1.5 mM
MgCl2; 20 pmol of primer; 0.2 mM each dATP, dGTP, and dTTP; 5 M dCTP;
1 Ci of [-32P]dCTP (3000 Ci/mmol; DuPont New England Nuclear, Boston,
MA); 50 ng of sample DNA; 1 PCR buffer; and 1.25 units of Taq DNA
polymerase (Life Technologies, Inc., Grand Island, NY). After denaturation at
95°C for 5 min, DNA amplification was performed for 25–30 cycles. Each
cycle consisted of denaturation at 95°C for 30 s, primer annealing at 55°C for
30 s, and elongation at 72°C for 15 s. PCR products were separated in 6%
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polyacrylamide gels, followed by autoradiography for single-strand conforma-
tional polymorphism analysis. The PCR products were also sequenced using an
ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA).
Two-Dimensional Electrophoresis. GIST tissues were suspended in sam-
ple buffer containing 40 mM Tris, 7 M urea, 2 M thiourea, 4% 3-[(3-Cholami-
dopropyl)dimethylammonio]-1-propane sulfonate (CHAPS), 100 mM 1,4-
dithioerythritol, and protease inhibitor cocktail (Roche, Mannheim, Germany).
Suspensions were sonicated for 30 s and centrifuged at 100,000  g for 45
min. One mg of total GIST protein was used for each electrophoresis. Aliquots
of proteins in sample buffer were applied onto immobilized pH 3–10 nonlinear
gradient strips (Amersham Pharmacia Biotech, Uppsala, Sweden). Isoelectric
focusing was conducted at 80,000 Vh. The second-dimension electrophoresis
was carried out in 9–16% linear gradient polyacrylamide gels (18 cm  20
cm  1.5 mm) as described previously (15). After protein fixation in 40%
methanol and 5% phosphoric acid for 12 h, gels were stained with Coomassie
Blue G250 for 24 h. Gels were destained with H2O and scanned in a Bio-Rad
G710 densitometer, and data were converted into electronic files, which were
then analyzed with Melanie III computer software (GenBio, Geneva, Switzer-
land).
Identification of Protein Spots. For mass spectrometry fingerprinting,
protein spots were directly cut out of the gels, destained, and treated with
trypsin. Aliquots of the peptide mixtures obtained from trypsin treatment were
applied onto a target disk and allowed to air-dry. Spectra were obtained using
a Voyager DE PRO MALDI-TOF spectrometer (Applied Biosystems, Foster
City, CA). Protein database searching was performed with MS-Fit5 using
monoisotopic peaks. A mass tolerance was first allowed within 50 ppm, and
then recalibration was performed at 20 ppm after obtaining the protein lists.
Western Blot Analysis. For Western blot analysis, tumor tissues and
matched nontumorous smooth muscle tissues were suspended in ice-cold lysis
buffer [50 mM Tris (pH 7.4), 1% Triton X-100, 5 mM EDTA, 1 mM KCl, 140
mM NaCl, 2 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 mM sodium
fluoride, 1% aprotinin, 1 uM leupeptin, and 1 mM sodium orthovanadate] for 15
min. Suspensions were sonicated for 30 s and centrifuged at 20,000  g for
15 min. For nuclear and cytoplasmic protein fractionation, five GISTs (three
GISTs with KIT mutation and two GISTs without KIT mutation) that had
sufficient amounts of tissue for preparation of tissue lysates were selected.
Nuclear and cytoplasmic extracts were prepared as described previously (16,
17). Approximately 0.3 g of frozen tissue was added to a cryogenic vial
containing 1 ml of buffer A [10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM
EDTA, 0.1 mM EGTA, 1 mM DTT, and 0.5 mM phenylmethylsulfonyl fluo-
ride], and homogenized. The cells were allowed to swell on ice for 15 min,
after which 50 l of 10% NP40 were added. After vigorous vortexing for 10 s,
the homogenate was centrifuged for 30 s. The supernatant was collected and
used for cytoplasmic protein assay. The pellet was resuspended in 100 l of
ice-cold buffer C [20 mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, and 1 mM phenylmethylsulfonyl fluoride] and shaken at
4°C for 15 min on a shaking platform. After being centrifuged for 5 min at 4°C,
the supernatant was collected and used for nuclear protein assay. Twenty g
of total protein lysates and cytoplasmic extracts and 5 g of nuclear protein
extracts were loaded into each lane, size-fractionated by SDS-PAGE, and
transferred to a polyvinylidene difluoride membranes that were blocked with
Tris-buffered saline-Tween 20 containing 5% skim milk. Primary antibodies,
KIT (C-19, polyclonal; Santa Cruz Biotech, Santa Cruz, CA), HMGB1 (poly-
clonal; BD Biosciences, Franklin Lakes, NJ), MMP2 (42–5D11, monoclonal;
Calbiochem, Temecula, CA), glyceraldehyde-3-phosphate dehydrogenase
(G3PDH; polyclonal; Trevigen, Gaithersburg, MD) were diluted 1:5000 in
blocking buffer and incubated for 1 h at room temperature. After washing,
membranes were incubated for 1 h with horseradish peroxidase-conjugated
secondary antibody (Amersham Pharmacia Biotech), washed, and then devel-
oped with ECL-Plus (Amersham Pharmacia Biotech).
Immunohistochemical Analysis. Formalin-fixed and paraffin-embedded
tissues were used for the immunostaining of KIT and HMGB1. Deparaffiniza-
tion and rehydration were performed using xylene and alcohol. The sections
were treated with 0.3% hydrogen peroxidase for 3 min and with blocking
antibody for 30 min. The same primary antibodies used for Western blotting
were applied in immunohistochemistry. The antibody against KIT protein was
applied at 1:1000 (v/v), whereas the antibody against HMGB1 was at 1:100
(v/v). Avidin-biotin complex methodology was used. The chromogen was
diaminobenzidine, and counterstaining was done with methyl green. The
evaluation of KIT was categorized as expressed and absent. The expression of
HMGB1 was categorized as overexpressed and normal. Cases with definite
nuclear staining in more than 30% of the tumor cells and/or cytoplasmic
expression were categorized as overexpressed, and cases with definite nuclear
staining in less than 30% of the tumor cells were categorized as normal.
RESULTS
Mutation Status of KIT. KIT mutations were found in 14 of 20
tumors. All of the mutations were present in exon 11. No mutations
were found in exons 9, 13, or 17. Deletion mutations were most
frequent and were found in eight cases, whereas point mutations were
found in four cases and insertions in two cases. Large deletions were
present between codons 550 and 558, and single amino acid deletions
were present at codons 560 and 579. The point mutations found were
V557R, V559D, and V559A, which have been previously reported in
GISTs.5 Internet address: http://prospector.ucsf.edu/ucsfhtml3.4/msfit.htm.
Table 1 Clinicopathological features, KIT mutation status, and HMGB1 expression levels of GISTs
Sample no.
Tumor size
(cm) Tumor type Anatomic site Sex Age
Comparative ratio of
HMGB1 expression
Type of KIT mutationWestern blot 2DEa
1 1 Benign Body F 38 2.5 3.7 P551_V555del
2 2.5 Benign Body M 64 1.0 0.9
3 4 Benign Body M 45 2.9 3.1 V559D
4 4 Benign Body F 36 3.7 3.3 M552_Y553del
5 7 Borderline Body M 52 2.2 3.1 W557R
6 5 Borderline Antrum F 47 0.1 0.2
7 4 Borderline Fundus M 79 1.7 4.2 D579del
8 8 Borderline Fundus F 76 2.3 5.9 V560del
9 9 Borderline Body M 45 1.2 1.6 T574_R586ins
10 5.5 Borderline Fundus F 52 0.2 0.2
11 17 Borderline Fundus F 64 2.7 3.8 D579del
12 5 Borderline Body F 56 0.7 0.1
13 12 Borderline Body F 57 2.8 4.9 V559A
14 13 Borderline Body M 49 1.2 1.1 L576_R586ins
15 10 Malignant Body M 35 0.2 0.2
16 17 Malignant Body M 78 1.0 1.0
17 22 Malignant Antrum M 64 2.9 3.7 W557_K558del
18 3.7 Malignant Fundus M 44 2.3 5.0 K550_K558del
19 5.5 Malignant Body F 68 3.3 3.6 V559D
20 6 Malignant Body M 58 2.3 4.6 Y553_Q556del
a 2DE, two-dimensional electrophoresis; del, deletion; ins, insertion.
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Two-Dimensional Electrophoresis Analysis of GISTs. Proteome
analysis was performed on GISTs by high-resolution two-dimensional
electrophoresis. More than 1000 protein spots were detected on the
two-dimensional electrophoresis gels and localized in the ranges of pI
3–10 and a relative molecular mass of 10–200 kDa. We were able to
identify more than 250 protein species in two-dimensional electro-
phoresis gels using MALDI-TOF spectrometry. Because matched
normal tissues with the same histogenetic origin cannot be obtained in
GISTs, we performed computer-assisted comparative analysis of the
respective Coomassie Blue spot patterns of GISTs with and without
KIT mutation or of benign and malignant GISTs. Accordingly, we
found that HMGB1 [formerly named HMG1 (Ref. 18; Fig. 1A] was
overexpressed in GISTs with KIT mutation.
Identification of HMGB1 as a Tumor Marker of GISTs with
KIT Mutation. We focused on the expression of HMGB1 because
some of the reported functions of HMGB1 are related to tumor growth
and metastasis. Both the pI and the relative molecular mass of
HMGB1 in each two-dimensional electrophoresis gel were deter-
mined by comparison with standard two-dimensional electrophoresis
gels from the Swiss-Two-Dimensional-PAGE database. As shown in
Fig. 1B, HMGB1 was overexpressed in GISTs with KIT mutation
compared with the GISTs without KIT mutation. The relative expres-
sion level of HMGB1 in all 20 of the samples analyzed by two-
dimensional electrophoresis was quantified using Melanie III com-
puter software (GenBio). In the 14 GISTs with KIT mutation, all of
the cases showed HMGB1 expression and 12 (86%) showed strong
expression level, more than three times higher in intensity than the
maximum observed in the six GISTs without KIT mutation (case 16).
In the six GISTs without KIT mutation, four cases showed no detect-
able HMGB1 expression, and the remaining two cases showed weak
expression. The expression of HMGB1 in colorectal carcinomas and
matched normal mucosae was ubiquitous; however, marked variations
were found. Of the 13 colorectal carcinomas, all of the tumors and
matched normal mucosae showed detectable HMGB1 expression, and
seven tumors showed more than three times higher intensity than the
matched normal mucosae. Comparison of HMGB1 expression by
volume percentage showed higher level expression in colorectal car-
cinomas and GISTs than in the nontumorous colon mucosae; the
average volume percentage was 0.23  0.19 for GISTs, 0.31  0.14
for colorectal carcinomas, and 0.08  0.06 for nontumorous colon
mucosae. To further examine the molecular characteristics of
HMGB1, the HMBG1 spot in two-dimensional electrophoresis was
Fig. 1. Two-dimensional electrophoresis of HMGB1. A, two-dimensional electrophoresis of GIST tissue (case 13). The proteins from GIST were extracted and separated on pH 3–10
nonlinear immobilized pH-gradient strips and were run through a 9–16% SDS/polyacrylamide gel. The gel was stained with Coomassie Blue G250, and protein spots were examined
by MALDI-TOF. B, two-dimensional electrophoresis gel images of HMGB1. Eight representative tissues of 20 cases are shown. Arrows, the protein spot corresponding to HMGB1.
C, MALDI-TOF peptide mass spectrum of the tryptic digest of HMGB1; T, trypsin autolytic fragments.
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isolated and subjected to trypsin digestion followed by MALDI-TOF
analysis. HMGB1 was validated by mass fingerprinting of the selected
peaks of peptides by applying low tolerance (20 ppm) with recali-
bration (Fig. 1C). For HMGB1, a total of six peaks were detected with
37% coverage (Table 2). This information led us to believe that the
proteins detected in 20 samples by two-dimensional electrophoresis
were authentic HMGB1. These HMGB1 spots on two-dimensional
electrophoresis also showed the expected mass profiles that were well
matched with the theoretical values of HMGB1.
Western Blot and Immunohistochemical Analysis for KIT and
HMGB1. To determine the relative protein expression levels of both
KIT and HMGB1, in which the former was not detectable in two-
dimensional electrophoresis under the same conditions, Western blot
analysis was carried out using antibodies against KIT and HMGB1
(Fig. 2). KIT expression was strong in GISTs with KIT mutation, and
this overexpression was directly related to mutation, regardless of the
mutation type. The relative expression ratio of KIT was 3.6 in cases
with KIT mutation and 0.5 in cases without KIT mutation. As ex-
pected, HMGB1 was found to be consistently overexpressed in GISTs
with KIT mutation. In accordance with the two-dimensional electro-
phoresis results, 11 of 14 GISTs with KIT mutation showed more than
a 2-fold overexpression of HMGB1 compared with the maximally
expressed HMGB1 level in those without KIT mutation (case 16). To
determine whether the overexpression of HMGB1 is related to MMP
expression, we performed Western analyses for MMP2 and found that
all 12 of the cases with HMGB1 overexpression also strongly ex-
pressed MMP2 (Fig. 2). This result is consistent with the previous
report by Taguchi et al. (19), in which secreted HMGB1 was found to
induce MMP expression. The results of Western blot analysis for
HMGB1 expression in colorectal carcinomas were also correlated
with the results of the two-dimensional electrophoresis. HMGB1
expression was found in most of the normal mucosae and tumors, and
overexpression was noted in 10 of 13 tumors. The nuclear and
cytoplasmic expression of HMGB1 was separately measured in five
GISTs (three GISTs with KIT mutation and two without KIT muta-
tion) by using fractionated nuclear and cytoplasmic protein lysates.
All three of the GISTs with KIT mutation showed variable amounts of
HMGB1 expression in the nuclear and cytoplasmic proteins, whereas
weak or undetectable cytoplasmic expression was found in the two
GISTs without KIT mutation, and one GIST without KIT mutation
also showed no detectable nuclear HMGB1 expression (Fig. 3). In-
terestingly, KIT expression was correlated to the cytoplasmic expres-
sion level of HMGB1 and MMP2 (Fig. 3). Immunohistochemically,
HMGB1 was detected mainly in the nuclei of the tumor cells, cyto-
plasms of some tumor cells, and some nuclei of the normal cells (Fig.
4). In 14 GISTs with KIT mutation, 12 showed nuclear HMGB1
expression, and 4 showed cytoplasmic HMGB1 expression. In six
GISTs without KIT mutation, two showed nuclear HMGB1 expres-
sion and one showed cytoplasmic HMGB1 expression. In the colo-
rectal carcinomas, stronger HMGB1 expression compared with that of
the normal mucosal cells was found in most of the tumor cells;
however, the level of expression between tumors was variable.
DISCUSSION
In this study, 20 GISTs were investigated for the mutation status of
KIT and the characteristics of their protein expression. We found
frequent mutations in exon 11 of KIT in our GISTs, and strong
expression of KIT and HMGB1 in cases with KIT mutation.
Frequent mutations of KIT in GISTs had been reported by many
laboratories (3, 5, 10, 11). In agreement with the previous reports, we
found frequent mutations (14 of 20, 70%) in our GISTs. Most of the
mutations were deletions (8 of 14, 57%) in exon 11, as has been
previously reported. Exon 11 constitutes the juxtamembrane region of
KIT, which serves as an antidimerization domain. Deletions, inser-
tions, or point mutations in this domain result in the activation of
tyrosine kinase activity by allowing ligand-independent receptor
dimerization (8, 9). Recently germ-line and somatic point mutations
of exon 13 (K642E) were reported and were found to be activating
mutations in the kinase domain of KIT gene (11). In this study, we
provide direct evidence of KIT protein overexpression in all of our
GISTs with KIT mutation. KIT overexpression in GISTs is a well-
Table 2 Summary of MALDI-TOF masses obtained from tryptic digests of human HMGB1a
Masses submitted
Monoprotonated masses
matched Delta ppm Start End Proposed peptide sequence
1128.5714 1128.5689 2.1 155 163 (K) YEKDIAAYR(A)
1510.6861 1510.6823 2.5 13 24 (K) MSSYAFFVQTCR(E)
1520.8392 1520.8437 2.9 113 127 (K) IKGEHPGLSIGDVAK(K)
1526.6745 1526.6772 1.7 13 24 (K) MSSYAFFVQTCR(E)
1592.7695 1592.7709 0.9 30 43 (K) KHPDASVNFSEFSK(K)
1592.7695 1592.7709 0.9 31 44 (K) HPDASVNFSEFSKK(C)
1592.7695 1592.7379 19.9 128 141 (K) KLGEMWNNTAADDK(Q)
2016.0203 2016.0166 1.8 97 112 (K) RPPSAFFLFCSEYRPK(I)
a A total of 37% sequence coverage.
Fig. 2. Mutation of KIT exon 11 by PCR-single-strand
conformational polymorphism analysis, and protein ex-
pression of KIT, HMGB1, and MMP2 in nine GIST
tissues and matched normal smooth muscle tissues by
Western blot analysis. Case 4 was benign, cases 5–8 were
borderline, and cases 15–18 were malignant GISTs. Im-
munoblotting with KIT, HMGB1, and MMP2 antibodies
after SDS-PAGE was performed as described in “Mate-
rials and Methods.” Glyceraldehyde-3-phosphate dehy-
drogenase (G3PDH) was used as the reference for com-
parisons between normal gastrointestinal smooth muscle
tissue and GIST. N, normal smooth muscle tissue; T,
GIST tissue. kDa, Mr in thousands.
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known characteristic, and is currently used as a diagnostic marker.
Most of the previous studies regarding KIT expression in GISTs in
human tissues were performed by using immunohistochemistry, and
quantitative evaluations of KIT expression and comparisons between
this and KIT mutations has not been performed. We applied Western
blot by using fresh tumor samples, thus enabling relative quantifica-
tion by Western blot, and we compared the results with KIT mutation
data. We found that KIT overexpression was directly related to KIT
mutation regardless of the mutation type. The ubiquitous KIT activa-
tion in GISTs by activating KIT mutation (12) and its roles have
previously been suggested epidemiologically (10, 12, 20). In addition,
there have been a number of reports on the aberrant expression of KIT
in other tumors (21–23) and on the relationship between KIT activa-
tion and the protection of apoptosis and the enhancement of tumor
invasion (24). On the basis of these reports, we suggest that mutations
of exon 11 of KIT induce the overexpression and the constitutive
activation of KIT, which subsequently plays a role in tumor transfor-
mation and progression.
Initially, this work was designed as part of our attempts to identify
a set of protein biomarkers involved in the progression of malignant
tumors by proteome analysis. We used GISTs for the following
reasons: (a) there are well-defined diagnostic criteria for differentiat-
ing benign, borderline, and malignant tumors; (b) most GISTs show
similar chromosomal, morphological, and immunohistochemical
characteristics; and (c) there are high percentages of tumor cells in
GIST. During the course of this work, we found that several proteins
are overexpressed in GISTs with KIT mutation, and, thus, we focused
on the cause and consequence of HMGB1 overexpression in GISTs
with KIT mutation. The implications of our proteome analysis are at
least 3-fold. The direct link between KIT mutation and HMGB1
expression should be regarded as a novel finding. We found HMGB1
expression in all 14 of the GISTs with KIT mutation, and 12 of these
showed very strong expression by two-dimensional electrophoresis
analysis. In GISTs without KIT mutation, HMGB1 was not expressed
in four of six GISTs. Interestingly, two GISTs with insertion muta-
tions in the distal portion of exon 11 of KIT showed low levels of
HMGB1 expression. From these results, we suspect that the consti-
tutive activity of KIT caused by these two insertion mutations in the
distal portion of exon 11 would be milder than that caused by
mutations in the proximal portion of the juxtamembrane domain.
Although the number of inserted sequences is not identical to ours,
similar insertional mutations at the same sites have been reported
previously (12), and further functional study of these two insertion
mutations is needed.
We demonstrated that the tumor cells are the origin of overex-
pressed HMGB1 in our GISTs by immunohistochemical analysis.
HMGB1 was abundantly expressed in the nuclei of the tumor cells
and/or some of the tumor cell cytoplasms, and the expression was
correlated with the result of two-dimensional electrophoresis and
Western blot analysis. We also demonstrated marked variation of
HMGB1 expression in colorectal carcinomas. Variations in HMGB1
expression at the RNA level had been reported in breast carcinomas
(25), gastric carcinomas (26), and hepatocellular carcinomas (27).
Overexpression of HMGB1 and cisplatin resistance had been reported
(28), and the role of HMGB1 in the repair of cisplatin-DNA adduct
had been proposed (28, 29). The marked intertumoral variation of
HMGB1 expression level and the reported roles of HMGB1 in tissue
differentiation and tumor progression raise the possibility that the
roles of HMGB1 in tumor differentiation and progression may be
different according to the HMGB1 expression level.
One of the important roles of the KIT mutation of GISTs in
tumorigenesis may be the activation of signal transduction pathways
of the cell cycle. In this study, we found that KIT, HMGB1, and
MMP2 are concomitantly overexpressed in GISTs with KIT mutation,
and, thus, HMGB1 and MMP2 may be downstream target molecules
in GISTs with KIT mutation. HMGB1 was originally identified as a
chromosomal DNA-binding protein (30). Apart from this intranuclear
function, HMGB1 was also shown to be localized in the extracellular
medium of different cell types as matrix-bound and in soluble mole-
cules (31) and to have an extracellular function in inflammation and
tumor metastasis (19, 32, 33). On the basis of the reported function of
HMGB1, the role of HMGB1 overexpression in GIST tumorigenesis
Fig. 4. Immunohistochemical analysis of HMGB1 in GISTs. Expression of HMGB1 is
noted in the nuclei of epithelial cells and inflammatory cells in the gastric mucosa (A) and
in the nuclei of smooth muscle cells (B). Microscopic feature of a GIST with KIT mutation
(C), which shows strong nuclear and cytoplasmic HMGB1 expression (D). Histology of
a GIST without KIT mutation (E) showing no HMGB1 expression in tumor cells. HMGB1
expression is evident only in the nuclei of the vascular smooth muscle cells and capillary
endothelial cells (F).
Fig. 3. Analysis of HMGB1 expression in nuclear and cytoplasmic proteins. A,
HMGB1 expression in total protein lysates of five GISTs. Cases 13T, 7T, and 19T were
positive for KIT mutation and cases 10T and 12T had no KIT mutation. B, analysis of
HMGB1, KIT, and MMP2 expression in the nuclear and cytoplasmic protein fraction of
five GISTs. Preparation of total protein lysates, nuclear protein fraction, and cytoplasmic
protein fraction was performed as described in “Materials and Methods.” Tn, nuclear
protein lysates from GIST tissue; Tc, cytoplasmic protein lysates from GIST tissue. kDa,
Mr in thousands.
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can be explained in two ways. First, overexpressed HMGB1 can
influence the expression and function of several related genes.
HMGB1 is mainly localized in the nucleus and interacts with several
transcription factors, by binding to the minor groove of DNA (33),
increasing the binding affinity of several transcription factors, (34)
and down-regulating the binding affinity of p53 and p73 in the human
BAX promoter (35). Thus, we suggest that the overexpression of
HMGB1 can contribute to tumorigenesis by altering tumor suppressor
gene function. Second, HMGB1 directly activates signal transduction
pathways related to cellular proliferation and/or metastasis. In addi-
tion to its intracellular role, HMGB1 is also secreted and/or released
by certain cells and plays important roles in tumor growth, invasion,
and metastasis (19, 33). Secreted and/or released HMGB1 binds to
receptor for advanced glycation end products (RAGE), as a receptor-
ligand pair, and this complex activates several molecules, including
mitogen-activated protein kinase (MAPK) signaling molecules and
MMPs. The suppression of tumor growth and metastasis by blocking
RAGE-amphoterin (synonym of HMGB1) complex in mice had been
reported (19). Therefore, it is likely that, after necrosis some of the
overexpressed HMGB1 may exist in secreted forms or released forms
that are capable of facilitating tumor growth and metastasis. Although
we could not confirm that a portion of the HMGB1 in our GISTs was
in a secreted form, we demonstrated the presence of HMGB1 by
showing that MMP2 is selectively overexpressed according to
HMGB1 expression in our GISTs. Taken together, our results suggest
that KIT mutation in GISTs is strongly related to HMGB1 overex-
pression which may contribute to tumor growth and invasion.
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